EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Prediction of New-Onset Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy Using Machine Learning

Ree Lu, Heidi S Lumish, Kohei Hasegawa, Mathew S Maurer, Muredach P Reilly, Shepard D Weiner, Albree Tower-Rader, Michael A Fifer, Yuichi J Shimada

European Journal of Heart Failure · 2025

DOI: 10.1002/ejhf.3546 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Ree Lu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Cardiomyopathy, Hypertrophic, Machine Learning. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Columbia University Irving Medical Center Irving Institute for Clinical & Translational Research Precision Medicine Pilot Award, NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Atrial fibrillation (AF) is the most common sustained arrhythmia among patients with hypertrophic cardiomyopathy (HCM), leading to increased symptom burden and risk of thromboembolism. The HCM-AF score was developed to predict new-onset AF in patients with HCM, though sensitivity and specificity of this conventional tool are limited. Thus, there is a need for more accurate tools to predict new-onset AF in HCM. The objective of the present study was to develop a better model to predict new-onset AF in patients with HCM using machine learning (ML). Methods and results In this prospective, multicentre cohort study, we enrolled 1069 patients with HCM without a prior history of AF. We built a ML model (logistic regression with Lasso regularization) using clinical variables. We developed the ML model using the cohort from one institution (training set) and applied it to an independent cohort from a separate institution (test set). We used the HCM-AF score as a reference model. We compared the area under the receiver-operating characteristic curve (AUC) between the ML model and the reference model using the DeLong's test. Median follow-up time was 2.1 years, with 128 (12%) patients developing new-onset AF. Using the ML model developed in the training set to predict new-onset AF, the AUC in the test set was 0.84 (95% confidence interval [CI] 0.77–0.91). The ML model outperformed the reference model (AUC 0.64; 95% CI 0.54–0.73; DeLong's p < 0.001). The ML model had higher sensitivity (0.82; 95% CI 0.65–0.93) than that of the reference model (0.67; 95% CI 0.52–0.88). The ML model also had higher specificity (0.76; 95% CI 0.71–0.81) than that of the reference model (0.57; 95% CI 0.41–0.70). Among the most important clinical variables included in the ML-based model were left atrial volume and diameter, left ventricular outflow tract gradient with exercise stress and at rest, late gadolinium enhancement on cardiac magnetic resonance imaging, peak heart rate during exercise stress, age at diagnosis, positive genotype, diabetes mellitus, and end-stage renal disease.

Conclusion

Our ML model showed superior performance compared to the conventional HCM-AF score for the prediction of new-onset AF in patients with HCM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCardiomyopathy, HypertrophicMachine LearningHumansFemaleMaleMiddle AgedProspective StudiesROC CurveAgedRisk AssessmentFollow-Up StudiesRisk Factors

Stichwörter der Autor:innen

Atrial fibrillationHypertrophic cardiomyopathyMachine learningPrediction

Autor:innen und Institutionen

  • Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
  • Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Irving Institute for Clinical and Translational Research, Columbia University Irving Medical Center, New York, NY, USA.
  • Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Förderung

  • Columbia University Irving Medical Center Irving Institute for Clinical & Translational Research Precision Medicine Pilot Award
  • NIH HHS
  • NHLBI NIH HHS
  • NIA NIH HHS
  • Korea Institute of Oriental Medicine
  • American Heart Association
  • Feldstein Medical Foundation
  • Columbia University Irving Medical Center Marjorie and Lewis Katz Cardiovascular Research Prize

Zitieren

APA

Lu, R., Lumish, H. S., Hasegawa, K., Maurer, M. S., Reilly, M. P., Weiner, S. D., Tower-Rader, A., Fifer, M. A., & Shimada, Y. J. (2025). Prediction of New-Onset Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy Using Machine Learning. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3546

Vancouver

Lu R, Lumish HS, Hasegawa K, Maurer MS, Reilly MP, Weiner SD, et al. Prediction of New-Onset Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy Using Machine Learning. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.3546

BibTeX
@article{Lu2025,
  author = {Lu, Ree and Lumish, Heidi S and Hasegawa, Kohei and Maurer, Mathew S and Reilly, Muredach P and Weiner, Shepard D and Tower-Rader, Albree and Fifer, Michael A and Shimada, Yuichi J},
  title = {Prediction of New-Onset Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy Using Machine Learning},
  journal = {European Journal of Heart Failure},
  year = {2025},
  doi = {10.1002/ejhf.3546}
}
Kostenlos starten →